DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Emricasan is an investigational drug.
There have been 15 clinical trials for Emricasan. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Fibrosis, Liver Cirrhosis, and Fatty Liver. The leading clinical trial sponsors are Conatus Pharmaceuticals Inc., Histogen, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).
There are one hundred and ninety-one US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Emricasan
|Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19||Histogen||Phase 1|
|Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis||Conatus Pharmaceuticals Inc.||Phase 2|
|Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension||Conatus Pharmaceuticals Inc.||Phase 2|
Top disease conditions for Emricasan
Top clinical trial sponsors for Emricasan
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Emricasan||⤷ Try it Free||Methods of treating, inhibiting and/or preventing an auditory impairment||The United States of America as represented by the Department of Veterans Affairs (Washington, DC)||⤷ Try it Free|
|Emricasan||⤷ Try it Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||⤷ Try it Free|
|Emricasan||⤷ Try it Free||Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells||Massachusetts Eye and Ear Infirmary (Boston, MA)||⤷ Try it Free|
|Emricasan||⤷ Try it Free||Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors||Pfizer Inc. (New York, NY)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Emricasan||Australia||AU2017261372||2036-05-05||⤷ Try it Free|
|Emricasan||Canada||CA3023278||2036-05-05||⤷ Try it Free|
|Emricasan||China||CN107847398||2036-05-05||⤷ Try it Free|
|Emricasan||European Patent Office||EP3452003||2036-05-05||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|